Glaxosmithkline Pharmaceuticals Limited · NSE:GLAXO
Glaxosmithkline Pharmaceuticals — Investor Presentation (February 2020)
15 slides from Glaxosmithkline Pharmaceuticals's investor presentation, Feb 5, 2020
Slide 1: Presentation for Analyst Meet (exchange cover letter)
GlaxoSmithKline Pharmaceuticals ltd. GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +022 2495 9595 Fax No: +022 2495 9494 Web: www.gsk-india.com February 5, 2020 Email: askus@gsk.com To, BSE LIMITED THE NATIONAL STOCK EXC HANGE OF INDIA Phiroze Jeejeebhoy Towers Exchange Plaza, 5t
Slide 2: Analysts' Meet, 4 February 2020
Analysts’ Meet 4 February 2020
Slide 3: Agenda
Agenda Financial Performance YTD / Q3 2019-20 Vemgal Update Unexpected Development: Ranitidine India Growth Story Innovation Focus
Slide 4: Performance YTD / Q3 19-20
Performance YTD / Q3 19-20 YTD EBIDTA margin +1%; YTD EPS +11%; GP margin +3% Performance YTD Performance Q3 Q3 Sales Sales 770 Cr / -6% Underlying growth +6% Portfolio Value Growth Key Brands 479Cr +12% Rx Key Brands 304Cr +8% Vx Key Brands 176Cr +20% Portfolio Value Growth External Growth Key Bran
Slide 5: YTD 2019-20 – Performance v PY YTD
YTD 2019-20 – Performance v PY YTD Headline: Sales +3% , PAT before exceptional +11% Exceptional Charge 336 Cr from impairment and related costs • Gross Profit +3% from better pricing 2,449 2,377 mix and margin improvement due to • Employee Benefits underlying Portfolio Optimisation +8% mainly due t
Slide 6: Q3 2019-20 – Performance v PY
Q3 2019-20 – Performance v PY Headline: Sales - 6% , PAT (before exceptional) @ 9% Exceptional Charge 737 Cr from impairment and related costs Gross Profit +4% from better pricing mix • Employee Benefits underlying and margin improvement due to Portfolio +13% on LTI, wage inflation and Optimisation
Slide 7: Agenda
Agenda Financial Performance YTD / Q3 2019-20 Vemgal Update Unexpected Development: Ranitidine India Growth Story Innovation Focus
Slide 8: Background of Vemgal
Background of Vemgal ❑ Nashik – multi dose form facility; severely under invested. Need for remediation to maintain the Global GSK standards Situation ❑ Need to increase capacity to cope up with strong business growth ambition ; maintain market share and maintain commitment to patient safety Planned
Slide 9: Agenda
Agenda Financial Performance YTD / Q3 2019-20 Vemgal Update Unexpected Development: Ranitidine India Growth Story Innovation Focus
Slide 10: Unexpected Global Development: Ranitidine
Unexpected Global Development: Ranitidine – NDMA (N-nitrosodimethylamine) issue highlighted in mid Sept 2019 leading to voluntary recall of Zinetac – GSK continues to respond to queries from global regulatory authorities – The EMA has initiated an investigation into the potential root causes for the
Slide 11: Financial Evaluation
Financial Evaluation ❑ Alternate SKU production at site; Additional capital investment required hence low financial Options viability; explored ❑ Low volumes for alternate products leading to significant under utilization of capacity at Vemgal ❑Ranitidine issue resulted in under-utilization and trig
Slide 12: Agenda
Agenda Financial Performance YTD / Q3 2019-20 Vemgal Update Unexpected Development: Ranitidine India Growth Story Innovation Focus
Slide 13: 2019-2021: Accelerating India Rx profitable growth
2019-2021: Accelerating India Rx profitable growth Winning in right TAs Winning in channels Winning with HCPs virtually Increased SoV on key brands to Build trust with channels Established a model for digital drive growth in AI, Derma and Acquire/ Build capability to only promotion for 6 identified
Slide 14: Agenda
Agenda Financial Performance YTD / Q3 2019-20 Vemgal Update Unexpected Development: Ranitidine India Growth Story Innovation Focus
Slide 15: Innovation Focus
Innovation Focus Innovation • Continued success of Nucala (Mepolizumab) which is a humanised monoclonal antibody and indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients • Launch of Menveo vaccine for protection against meningococcal disease. • Continued commi
GlaxoSmithKline Pharmaceuticals — Investor Presentation (February 2020) on 6ix